Narges Fallahi , Mitra Rafiee , Ehsaneh Azaryan , David Wilkinson , Vahid Bagheri
{"title":"Inhibitory effects of progesterone on the human acute lymphoblastic leukemia cell line","authors":"Narges Fallahi , Mitra Rafiee , Ehsaneh Azaryan , David Wilkinson , Vahid Bagheri","doi":"10.1016/j.genrep.2024.101991","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Acute lymphoblastic leukemia (ALL) is a rare form of blood cancer that can quickly advance if left untreated. Research has suggested that progesterone (P4) may be effective in treating certain types of tumors. Specifically, the membrane progesterone receptors may play a role in either enhancing or inhibiting cell growth in various tumors. This study aimed to investigate the impact of P4 on inhibition of NALM6 cells.</p></div><div><h3>Methods</h3><p>NALM6 cells were exposed to different concentrations of P4 (ranging from 10 to 50 μM) at 24,48 and 72 h intervals. The cell survival rate was then evaluated using an MTT assay. Additionally, the study assessed the rate of mPR expression in the cells using flow cytometry at 48 and 72 h after P4 administration (at concentrations of 20 and 10 μM, respectively). Furthermore, the level of ROS was evaluated using the dichlorofluorescein diacetate (DCFDA) flow cytometry technique.</p></div><div><h3>Results</h3><p>The study found that mPR-β was expressed in NALM6 cells and that P4 had a significant inhibitory effect on the growth of tumor cells in a time and concentration-dependent manner. Furthermore, P4 was found to reduce mPR-β expression at 48 and 72 h. The treatment also resulted in a decrease in ROS levels compared to untreated cells (<em>P</em> ≤ 0.05).</p></div><div><h3>Conclusion</h3><p>The study suggests that p4 may be effective in growth-inhibiting NALM6 cells by decreasing cell viability and reducing ROS levels. However, further research is needed to understand the mechanism of action and interactions with various receptors and to confirm its effectiveness in treating NALM6 leukemia.</p></div>","PeriodicalId":12673,"journal":{"name":"Gene Reports","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452014424001146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Acute lymphoblastic leukemia (ALL) is a rare form of blood cancer that can quickly advance if left untreated. Research has suggested that progesterone (P4) may be effective in treating certain types of tumors. Specifically, the membrane progesterone receptors may play a role in either enhancing or inhibiting cell growth in various tumors. This study aimed to investigate the impact of P4 on inhibition of NALM6 cells.
Methods
NALM6 cells were exposed to different concentrations of P4 (ranging from 10 to 50 μM) at 24,48 and 72 h intervals. The cell survival rate was then evaluated using an MTT assay. Additionally, the study assessed the rate of mPR expression in the cells using flow cytometry at 48 and 72 h after P4 administration (at concentrations of 20 and 10 μM, respectively). Furthermore, the level of ROS was evaluated using the dichlorofluorescein diacetate (DCFDA) flow cytometry technique.
Results
The study found that mPR-β was expressed in NALM6 cells and that P4 had a significant inhibitory effect on the growth of tumor cells in a time and concentration-dependent manner. Furthermore, P4 was found to reduce mPR-β expression at 48 and 72 h. The treatment also resulted in a decrease in ROS levels compared to untreated cells (P ≤ 0.05).
Conclusion
The study suggests that p4 may be effective in growth-inhibiting NALM6 cells by decreasing cell viability and reducing ROS levels. However, further research is needed to understand the mechanism of action and interactions with various receptors and to confirm its effectiveness in treating NALM6 leukemia.
Gene ReportsBiochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.30
自引率
7.70%
发文量
246
审稿时长
49 days
期刊介绍:
Gene Reports publishes papers that focus on the regulation, expression, function and evolution of genes in all biological contexts, including all prokaryotic and eukaryotic organisms, as well as viruses. Gene Reports strives to be a very diverse journal and topics in all fields will be considered for publication. Although not limited to the following, some general topics include: DNA Organization, Replication & Evolution -Focus on genomic DNA (chromosomal organization, comparative genomics, DNA replication, DNA repair, mobile DNA, mitochondrial DNA, chloroplast DNA). Expression & Function - Focus on functional RNAs (microRNAs, tRNAs, rRNAs, mRNA splicing, alternative polyadenylation) Regulation - Focus on processes that mediate gene-read out (epigenetics, chromatin, histone code, transcription, translation, protein degradation). Cell Signaling - Focus on mechanisms that control information flow into the nucleus to control gene expression (kinase and phosphatase pathways controlled by extra-cellular ligands, Wnt, Notch, TGFbeta/BMPs, FGFs, IGFs etc.) Profiling of gene expression and genetic variation - Focus on high throughput approaches (e.g., DeepSeq, ChIP-Seq, Affymetrix microarrays, proteomics) that define gene regulatory circuitry, molecular pathways and protein/protein networks. Genetics - Focus on development in model organisms (e.g., mouse, frog, fruit fly, worm), human genetic variation, population genetics, as well as agricultural and veterinary genetics. Molecular Pathology & Regenerative Medicine - Focus on the deregulation of molecular processes in human diseases and mechanisms supporting regeneration of tissues through pluripotent or multipotent stem cells.